Provention Bio, Inc. PRVB
Set alert
24.98 +24.98 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 2.38B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -192.15
- Beta
- 2.46
- Short ratio
- 1.53
- Inst. own
- 53.26%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 4, 2023
- 50-d avg
- 19.10
- 200-d avg
- 10.15
- 1y target
- 23.50
Analyst view
Consensus: buy
Buy
Price target (mean) 23.50 -5.9% downside
Now 24.98
- Target (low)
- 19.00
- Target (mean)
- 23.50
- Target (high)
- 25.00
Recommendation trend
- 1 month ago 6
- 2 months ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.54 | -1.54 – -1.54 | -0.35 | -340.0% | 3.00M | +417.2% | 1 |
| Next quarter | -0.55 | -0.55 – -0.55 | -0.46 | -19.6% | 6.00M | +704.3% | 1 |
| Current year | -2.09 | -2.09 – -2.09 | -1.52 | -37.5% | 44.00M | +241.2% | 1 |
| Next year | -0.13 | -0.95 – 0.68 | -2.09 | +93.8% | 130.60M | +196.8% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 15, 2023 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Mar 14, 2023 | SMBC Nikko | Downgrade | Outperform | Neutral |
| Mar 14, 2023 | Jefferies | Downgrade | Buy | Hold |
| Mar 13, 2023 | Chardan Capital | Maintained | — | Buy |
| Feb 15, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Nov 21, 2022 | SVB Leerink | Maintained | — | Outperform |
| Nov 21, 2022 | Chardan Capital | Maintained | — | Buy |
| Nov 18, 2022 | Oppenheimer | Maintained | — | Outperform |
| Nov 18, 2022 | Jefferies | Maintained | — | Buy |
| Nov 4, 2022 | Chardan Capital | Maintained | — | Buy |
| Oct 7, 2022 | Jefferies | Maintained | — | Buy |
| Sep 20, 2022 | Jefferies | Initiated | — | Buy |
| Aug 5, 2022 | Chardan Capital | Maintained | — | Buy |
| Jul 11, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Aug 6, 2021 | Oppenheimer | Maintained | — | Outperform |
| Aug 6, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Apr 13, 2021 | Chardan Capital | Maintained | — | Buy |
| Apr 12, 2021 | HC Wainwright & Co. | Reiterated | — | Buy |
| Apr 9, 2021 | Cantor Fitzgerald | Maintained | — | Overweight |
| Apr 9, 2021 | RBC Capital | Downgrade | Outperform | Sector Perform |
| Apr 9, 2021 | SVB Leerink | Maintained | — | Outperform |
| Feb 22, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Jun 16, 2020 | Chardan Capital | Maintained | — | Buy |
| Jun 16, 2020 | HC Wainwright & Co. | Maintained | — | Buy |
| Jun 4, 2020 | Oppenheimer | Initiated | — | Outperform |
| Jun 4, 2020 | RBC Capital | Initiated | — | Outperform |
| Apr 2, 2020 | Chardan Capital | Maintained | — | Buy |
| Jan 24, 2020 | Cantor Fitzgerald | Initiated | — | Overweight |
| Jun 10, 2019 | Chardan Capital | Initiated | — | Buy |
| Jan 18, 2019 | H.C. Wainwright | Initiated | — | Buy |